Evidence for an involvement of the brain cholecystokinin B receptor in anxiety.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 1996314.
- Also identified by PMC identifier 50970.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The effect of neuropeptide cholecystokinin (CCK) receptor agonists and antagonists was examined in the rat elevated X-maze model of anxiety. The selective CCK-B receptor antagonists CI-988 (PD 134308) and L-365,260 produced anxiolytic-like effects, whereas MK-329, a CCK-A receptor antagonist, was respectively less potent by factors of 313 and 200. The intracerebroventricular administration of the nonselective CCK receptor agonist caerulein or the selective CCK-B receptor agonist pentagastrin increased dose dependently the level of anxiety. CI-988 dose dependently antagonized the anxiogenic response to pentagastrin but not that induced by pentylenetetrazol. These results strongly suggest that activation of the brain CCK-B receptor induces anxiety and that selective antagonists of this receptor represent a separate class of anxiolytic agents.
Medical subject headings
- Anxiety
- Benzodiazepinones
- Cerebral Ventricles
- Chlordiazepoxide
- Cholecystokinin
- Indoles
- Meglumine
- Phenylurea Compounds
- Receptors, Cholecystokinin